Research published in the journal Translational Psychiatry It has been found that vitamin D supplementation in people with vitamin D deficiency may reduce the lifetime risk of severe depression.
Study: Vitamin D, chronic pain and depression: Linear and nonlinear Mendelian randomization analyses. Image credit: Aria Armoko/Shutterstock
background
Vitamin D deficiency, defined as low blood levels of 25-hydroxyvitamin D, is known to affect bone biology, immune responses, and inflammation, leading to chronic pain. Results from several observational studies have highlighted an association between vitamin D deficiency and chronic pain, fibromyalgia, and depression.
Randomized controlled clinical trials of vitamin D supplementation in chronic pain patients have largely produced mixed results. In contrast, systematic reviews of randomized trials have highlighted the positive impact of vitamin D supplementation on depression, depressive symptoms, and negative affect.
Observational epidemiological studies can be subject to bias due to confounding factors and reverse causation. Mendelian randomization can overcome these challenges. This method uses genetic variants as instrumental variables to determine the causal effect of an exposure on an outcome, providing a more precise understanding of the causal relationship between vitamin D levels and chronic pain.
In Mendelian randomization analysis, genetic variants specifically associated with circulating vitamin D levels can be used as a surrogate for vitamin D status in the body to determine a causal relationship between vitamin D levels and chronic pain.
Gene variants are randomly distributed at conception and therefore unlikely to be associated with confounding factors. Furthermore, chronic pain conditions have no effect on genotype, eliminating the possibility of reverse causation.
In this study, the scientists used linear and nonlinear Mendelian randomization analyses to investigate the causal effect of circulating vitamin D concentrations on the outcomes of chronic pain and depression.
Study design
The scientists performed linear and non-linear Mendelian randomization analyses on individual-level data collected from the UK Biobank, which included approximately 500,000 participants aged 40–69 years at enrolment.
The scientists limited their analysis to 333,025 unrelated participants of European descent who had valid measurements of vitamin D. They determined the causal effect of vitamin D levels on four outcomes, including the likelihood of fibromyalgia, clinical fatigue, chronic widespread pain, and lifetime major depression.
They used genetic variants in four genetic regions with known association with vitamin D biology as instrumental variables used to control for confounding factors and measurement error.
They conducted linear analyses to examine causal effects within the population and nonlinear analyses to determine causal effects within subgroups of the population. The subgroups were classified based on circulating levels of vitamin D.
Important Observations
Linear Mendelian randomization analysis revealed that genetically predicted vitamin D levels were not associated with the likelihood of fibromyalgia, clinical fatigue, chronic widespread pain, and lifetime severe depression.
Nonlinear Mendelian randomization analysis revealed that genetically predicted vitamin D levels were associated with depression in participants with the lowest blood vitamin D levels, although no such associations were observed for other outcomes tested.
Significance of the study
The study found that genetically predicted vitamin D levels were associated with the likelihood of lifetime severe depression in those with the lowest blood vitamin D levels. This finding suggests that vitamin D supplementation in people with vitamin D deficiency could reduce the risk of depression.
However, the study found no significant associations between genetically predicted vitamin D levels and the likelihood of fibromyalgia, clinical fatigue, chronic widespread pain, or lifetime severe depression, suggesting that taking vitamin D supplements is unlikely to reduce the risk of these outcomes in the population as a whole.
Overall, this study indicates that the beneficial effects of vitamin D supplements are limited to people with vitamin D deficiency, and taking supplements above threshold levels is unlikely to provide any additional benefit.
Considering these observations, the scientists recommend that future clinical trials of vitamin D supplementation should focus on recruiting larger groups with vitamin D deficiency to more realistically determine the beneficial effects of this vitamin.
Some mechanistic studies have proposed that vitamin D may play a role in reducing the risk of depression through its anti-inflammatory effects. Recent animal studies have shown that circulating vitamin D deficiency may affect gut microbiota diversity, which is associated with mood disorders. Vitamin D has also been observed to affect the hypothalamic-pituitary-adrenal axis through interactions with glucocorticoids, which are known to be involved in the development of depression.
The study was conducted on individuals of European descent, which may limit the generalizability of the findings to other populations. Furthermore, general population studies suggest that the lifetime prevalence of major depression is around 10-20 percent, whereas the study identified only around 4 percent of UK Biobank participants with depression, highlighting the possibility that some cases may be missed.
